Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea by Hong, J.-L. et al.
Differential Use of Screening Mammography in Older Women
Initiating Metformin versus Sulfonylurea
Jin-Liern Hong1* , Louise M. Henderson1,2, Michele Jonsson Funk1, Jennifer L. Lund1, John B. Buse3,
Virginia Pate1 and Til Stürmer1
1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA
2Department of Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
ABSTRACT
Purpose Differential use of screening mammography may lead to biased detection of breast cancer. This study aimed to compare receipt of
screening mammography and the incidence of screen-detected breast cancer between metformin and sulfonylurea initiators.
Methods We used 2006-2014 US Medicare claims to identify initiators of metformin or sulfonylurea aged 65+ years continuously enrolled
in Parts A/B for ≥2 years pre-initiation and ≥2 years post-initiation. We reported frequencies of screening mammograms and screen-detected
breast cancer in 1 year pre-initiation among all cohort members and in 1 year post-initiation among cancer-free cohort members. Weighted
screening risk differences (RDs) were estimated comparing metformin to sulfonylurea group.
Results We identified 41,436 and 13,367 initiators of metformin and sulfonylurea, 35% and 24% of which had ≥1 screening mammogram
in 1 year pre-initiation (weighted RD: 6 percentage points; 95% CI: 5 to 7), respectively. The weighted RD for screen-detected breast cancer
associated with metformin was 0.00 percentage points (95% CI: -0.09 to 0.09). Among cancer-free cohort members, metformin initiators had
5 percentage points (95% CI: 4 to 6) and 0.11 percentage points (95% CI: -0.02 to 0.23) absolute risk excess of screening mammography and
screen-detected breast cancer in 1 year post-initiation, compared with sulfonylurea initiators, respectively.
Conclusions Metformin initiators were more likely to receive screening mammograms than sulfonylurea initiators pre- and post-initiation,
indicating possible detection bias due to differential screening mammography. Researchers should be aware of the potential for more screen-
ing mammograms pre- and post-initiation when interpreting the findings of metformin on breast cancer incidence. Copyright © 2017 John
Wiley & Sons, Ltd.
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INTRODUCTION
Metformin is the most commonly prescribed drug for
type 2 diabetes. It has been linked with possible bene-
ficial effects on breast cancer incidence in several
observational studies1–4 but not in others.5–11 Many
of the studies reporting an inverse association between
metformin and breast cancer risk may suffer from
time-related biases.12 Another potential source of bias,
detection bias due to differential healthcare utilization,
could also affect the metformin-breast cancer associa-
tion but has not been addressed to date. Differential
detection of asymptomatic or pre-clinical cancer
before metformin initiation could reduce cancer
incidence after initiation by excluding women whose
breast cancer was detected at an early stage. On the
other hand, differential detection after metformin initi-
ation may lead to an increased incidence rate immedi-
ately following treatment initiation followed by a
period of reduced incidence rate.
Our previous study examined healthcare utilization
comparing metformin and a clinical alternative, sulfo-
nylurea, using data from Medicare claims.13 We have
noted that metformin initiators were more likely than
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history of cancer. This cancer-free cohort was a
subgroup of the new user cohort, which included eligi-
ble initiators without a diagnosis of any cancer except
for non-melanoma skin cancer within 12 months
before initiation. The flowchart of the study cohort is
available in Supplemental Figure S1.
Screening Mammography
We used the following Healthcare Common Procedure
Coding System (HCPCS) codes to select all bilateral
mammograms for the study cohort: G0202-G0205,
76091-76092, 77051-77052, and 77056-77057. Mam-
mograms were further classified as either screening
versus diagnostic using a claims-based algorithm14.
Briefly, mammograms were considered as screening
if they were coded as screening mammography
without a previous mammogram within the prior 9
months and without a breast cancer diagnosis in the
prior year. This algorithm has been validated in
Medicare claims with a positive predictive value
(PPV) of 94.9%14. Our application of this algorithm
identified 36,164 (83%) and 16,855 (91%) screening
mammograms out of 43,333 and 18,504 total mammo-
grams in the new user cohort and the cancer-free
cohort, respectively (Supplemental Figures S2-S3).
Only screening mammograms were included in the
analysis.
Screen-Detected Breast Cancer
After distinguishing screening from diagnostic mam-
mograms, we used the Fenton algorithm to identify
incident screen-detected breast cancers.15 This
algorithm has a PPV of 88.0% among Medicare
enrollees.15 The Fenton algorithm classifies screening
mammograms as positive to detect breast cancer by
requiring a breast cancer diagnosis within 123 days
post-screening mammogram and a breast-directed
surgery within a year following the diagnosis, or by
a diagnosis of ductal carcinoma in-situ within 286
days post-screening mammogram with a subsequent
mammogram within 82 days following the diagnosis.
Our application of this algorithm and the results are
shown in Supplemental Figures S4-S5. We further
calculated the screening detection rate for breast
cancer by dividing the number of screen-detected
breast cancers by the number of screening
mammograms.
Incident Breast Cancer
In the cancer-free cohort, any incident breast cancer
during the 12-month follow-up was another outcome
sulfonylurea initiators to receive mammograms and to 
visit physicians around the time of initiation, poten-
tially leading to biased detection of breast cancer. 
However, this study failed to distinguish screening 
from diagnostic mammography, thus the results did 
not reflect the actual difference in receipt of screening 
mammography between metformin and sulfonylurea 
initiators. Therefore, the objective of this study was 
to quantify the risk of screening mammography and 
screen-detected breast cancer over 12-month periods 




This study used data from Medicare fee-for-service 
beneficiaries from January 1st, 2006 to December 
31st, 2014. Medicare offers free screening mammogra-
phy annually for women with Medicare aged 40+, 
minimizing the influences of socioeconomic disparity. 
Given that differential detection pre- and post-
initiation would affect breast cancer incidence 
estimates differently, this study included two study 
cohorts. One was the new user cohort which examined 
use of screening mammography over a two-year 
window (12 months pre- and post-initiation), primarily 
focusing on the period of 12 months before drug 
initiation. The second study cohort was the cancer-free 
cohort mimicking a cohort study on breast cancer 
incidence excluding individuals diagnosed with any 
cancer before drug initiation, and only examined use 
of screening mammography in 12 months after 
initiation.
For the new user cohort, we identified women aged 
65 or older who initiated monotherapy of metformin or 
sulfonylurea between 2008 and 2012. Initiation was 
defined as having ≥1 refill within 90 days after end 
of drug supply of the initial prescription and having 
≥12 month period of continuous Part D enrollment 
before initiation without use of any anti-
hyperglycemic drugs. Patients were classified as 
initiators of metformin or sulfonylurea according to 
the initial prescription and the date of the first prescrip-
tion was defined as the index date. Eligible patients 
were also required to be enrolled in Part A and B con-
tinuously for ≥24 months pre-initiation and ≥24 
months post-initiation, thus patients who died or dis-
enrolled Medicare Part A and B within 24 months after 
initiation were excluded from the study.
We utilized the cancer-free cohort to assess receipt 
of screening mammography within 12 months 
following treatment initiation among women with no
characteristics and the proportion of women who had
≥1 screening mammogram in 2 years between metfor-
min and sulfonylurea initiators, respectively. Over a
two-year window, 47% of the new user cohort
received ≥1 screening mammogram. We identified
29,597 and 6,567 screening mammograms over two
years in 50% of metformin initiators and 36% of sulfo-
nylurea initiators, respectively. The proportion of
women receiving screening mammograms decreased
with age but increased with number of physician visits
in both groups. Screening mammography was less
common in the patients with comorbidity, such as
those with cardiovascular disease or hospital admis-
sion, but remained similar across calendar years.
We present the proportion of patients receiving
screening mammograms in 3-monthly intervals over
12 months before and after initiation in Figure 1.
Metformin initiators were more likely to have screen-
ing mammograms than sulfonylurea initiators, which
was consistent over time. For both cohorts, the
percentage of patients receiving screening mammo-
grams peaked in the 3 months immediately following
initiation in metformin initiators, but was fairly stable
over time.
Comparing metformin to sulfonylurea initiators, the
weighted RD of screening mammography over the
two-year window was 8 percentage points (95% CI:
7 to 9) (Table 2). The results were similar before and
after initiation. We identified 197 and 37 incident
breast cancers that were detected on screening mam-
mograms among metformin and sulfonylurea groups,
respectively (Table 2). The risk of incident screen-
detected breast cancer was 0.48% in metformin, as
compared with 0.28% in sulfonylurea, with a weighted
RD of 0.11 percentage points (95% CI: -0.03 to 0.25).
A higher absolute risk of screen-detected breast cancer
was observed for the metformin group in the 12
months after initiation (weighted RD: 0.11 percentage
points; 95% CI: 0.00 to 0.21), but not during the 12
months before initiation.
In the cancer-free cohort, we observed similar
patient characteristics and patterns of screening
mammography and screen-detected breast cancer
during 12 months after initiation in the cancer-free
cohort (Supplemental Table S2 and Table 3).
Metformin initiators in the cancer-free cohort were
also more likely to receive screening mammograms
than sulfonylurea initiators (weighted RD: 5 percent-
age points; 95% CI: 4 to 6). The risk of screen-
detected breast cancer was higher in metformin
(0.32%) than sulfonylurea (0.13%), but differences
became attenuated after accounting for imbalances in
baseline characteristics (weighted RD: 0.11 percentage
of interest, irrespective of whether it was detected 
by screening or due to symptoms. To be consistent 
with the Fenton algorithm, we required a breast-
directed surgery within a year following a diagnosis 
code for invasive breast cancer and required a mam-
mogram within 82 days after a diagnosis code for 
ductal carcinoma in-situ, to ascertain the breast can-
cer case.
Statistical Analysis
In the new user cohort, we calculated use of screening 
mammography in metformin and sulfonylurea 
initiators during a two-year window of 12 months 
pre- and post-initiation. The day of initiation was 
indexed as Month 0, and was included in the month 
following initiation (Month 1). Frequencies of initia-
tors receiving a screening mammogram were summa-
rized within sequential 3-month and 12-month 
intervals from Month -12 (before initiation) to Month 
12 (after initiation), respectively. Incident breast 
cancer detected at screening was calculated over 
12-monthly intervals, given expected small numbers. 
We estimated risks and risk differences (RDs) and 
their 95% confidence intervals (CIs) of each event 
during each time interval comparing metformin to 
sulfonylurea initiators. To control the measured 
confounders, we used propensity score weighting 
methods to standardize sulfonylurea initiators to 
metformin initiators on age, race, comorbidities, 
calendar year of initiation, and number of physician 
office visit.16
In the cancer-free cohort, we repeated all analyses 
during the time window of 12 months after initiation 
only and calculated RD of the incidence of any 
breast cancer comparing metformin to sulfonylurea 
groups in 12 months post-initiation. Given that 
screening mammography before initiation is likely 
associated with receiving subsequent screening tests 
after initiation, we additionally included the variable 
of prior screening in the propensity score model for 
confounding control. Furthermore, the analyses in 
the cancer-free cohort were stratified by receipt of 
screening mammography in 12 months before 
initiation.
All analyses are performed with the SAS software 
v9.3 (Cary, NC).
RESULTS
Our new user cohort included 41,436 initiators of 
metformin and 13,367 initiators of sulfonylurea during 
the study period. Table 1 summarizes the baseline
In the cancer-free cohort, we stratified the analyses
by receipt of screening mammography in the 12
months before initiation (Table 3). Women screened
in the 12 months pre-initiation were more likely to
receive screening mammograms in the 12 months after
initiation compared to those not screened before
initiation, in both metformin and sulfonylurea groups.
Table 1. Characteristics at baseline among metformin and sulfonylurea initiators in the new user cohort, and proportion of women receiving at least one




(%)†N (%) % screened* N (%) % screened*
Total No. 41,436 (100.0) 50.3 13,367 (100.0) 35.7 14.6
Age, years
Median 73 72§ 76 74§
Interquartile Range (IQR) (69-78) (69-77) (70-83) (69-80)
Category
65 - 69 12,256 (29.6) 54.0 3,077 (23.0) 39.1 15.0
70-74 12,159 (29.3) 57.7 2,609 (19.5) 47.9 9.8
75-79 8,115 (19.6) 51.9 2,549 (19.1) 41.0 10.9
80-84 5,295 (12.8) 41.0 2,442 (18.3) 33.2 7.8
85+ 3,611 (8.7) 22.9 2,690 (20.1) 17.1 5.8
Race
White 33,447 (80.7) 51.4 10,468 (78.3) 36.2 15.2
Black 4,237 (10.2) 49.5 1,823 (13.6) 37.4 12.1
Others 3,752 (9.1) 41.8 1,076 (8.0) 27.7 14.1
Comorbidity¶
Breast Cancer 2,361 (5.7) 9.7 715 (5.3) 7.7 2.0
Any Cancer 5,610 (13.5) 35.7 2,008 (15.0) 29.2 6.4
Congestive Heart Failure 5,066 (12.2) 35.6 3,187 (23.8) 26.5 9.2
Ischemic Heart Disease 9,992 (24.1) 45.5 4,521 (33.8) 33.7 11.8
Hypertension 34,737 (83.8) 50.9 11,412 (85.4) 36.4 14.5
HealthCare Utilization
Days of Hospitalization¶
0 33,653 (81.2) 52.6 9,173 (68.6) 38.9 13.8
1 to 7 5,364 (12.9) 44.0 2,481 (18.6) 30.4 13.6
8+ 2,419 (5.8) 31.9 1,713 (12.8) 26.0 5.9
No. of Physician Office Visit¶
≤ 3 6,184 (14.9) 31.8 2,467 (18.5) 19.4 12.4
4 to 6 4,971 (12.0) 41.9 1,419 (10.6) 26.3 15.7
7 to 12 10,303 (24.9) 52.1 2,973 (22.2) 35.0 17.1
13+ 19,978 (48.2) 57.2 6,508 (48.7) 44.2 13.0
Location
Mid West 10,522 (25.4) 52.8 3,441 (25.7) 37.2 15.6
North East 6,655 (16.1) 49.6 2,467 (18.5) 34.4 15.2
South 16,521 (39.9) 49.8 5,583 (41.8) 35.5 14.3
West 7,509 (18.1) 48.8 1,786 (13.4) 35.6 13.3
Others 220 (0.5) 38.2 82 (0.6) 22.0 16.2
Calendar Year of Initiation
2008 8,180 (19.7) 51.2 3,262 (24.4) 34.9 16.3
2009 8,365 (20.2) 51.0 2,993 (22.4) 36.0 15.0
2010 8,304 (20.0) 50.5 2,556 (19.1) 34.5 16.0
2011 8,310 (20.1) 49.7 2,317 (17.3) 36.2 13.5
2012 8,277 (20.0) 49.1 2,239 (16.8) 37.2 12.0
*% screened was calculated as proportion of women receiving ≥1 screening mammogram within 2-year window of 12 months before and after initiation
among the initiators. We also calculated the percentage of women screened in 1 year before and after initiation, respectively. The results are presented in
Supplemental Table S1.
†Screening Difference (%) was calculated as the difference in the proportion of women receiving ≥1 screening mammogram within a 2-year window of 12
months before and after initiation between initiators of metformin and sulfonylurea.
§The median (IQR) of age was calculated for women receiving ≥1 screening mammogram within 2-year window of 12 months before and after initiation for
each drug cohort.
¶Comorbidity was defined as the presence of one diagnosis code within 1 year prior to initiation. Days of hospitalization and number (no.) of physician office
visits were defined within 1 year prior to initiation.
points; 95% CI: -0.02 to 0.23). For any incident breast 
cancer within 1 year post-initiation, metformin was not 
associated with an altered risk (weighted RD: 0.09 
percentage points; 95% CI: -0.07 to 0.26); however, 
more breast cancer cases were detected by screening 
in metformin initiators (61%) than sulfonylurea 
initiators (37%).
(CDC). The CDC estimated 65.5% of women aged
65+ years in 2008 self-reported receiving a mammo-
gram within the past 2 years based on the National
Health Interview Survey17, but the self-reported rates
of cancer screenings tend to be overestimated.18,19 A
previous study using the 5% Medicare random sample
found similar results to ours, which reported 40.2% of
women aged 65+ years in Medicare during 2005-2006
had ≥1 screening mammography.20 We also observed
that receipt of screening mammography was associ-
ated inversely with age but positively with number of
physician visits, consistent with previous findings.20
The United States Preventive Services Task Force
(USPSTF) recommended yearly screening mammog-
raphy for women aged 40+ since 200221, but revised
the guideline to recommend biennial mammography
for women aged 50-74 years in 2009.22 Our study
found no difference in use of screening mammography
in women aged 65+ years across calendar years,
similar to previous national survey-based studies.17,23
Differential use of screening mammography
between metformin and sulfonylurea initiators could
be partially explained by age. Older women are less
likely to receive screening mammography (Table 1)
Figure 1. Proportions of women receiving a screening mammogram over time by treatment group, in the new user cohort (Top) and in the cancer-free cohort
(Bottom).
The positive association between metformin and 
higher risks of screen-detected and all breast cancer 
was found among women not screened pre-initiation, 
but not among women previously screened.
DISCUSSION
In this study, we found that older women initiating 
metformin were not only more likely to be screened 
for breast cancer in 12 months before initiation than 
women initiating sulfonylurea, but they were also 
more likely to have screening mammograms in the 
12 months after initiation. Consequently, compared 
with sulfonylurea initiators, metformin initiators had 
higher probabilities of screen-detected breast cancer, 
particularly after initiation. These results indicate 
existence of detection bias due to differential screening 
mammography pre- and post-initiation when 
comparing breast cancer incidence between women 
initiating metformin vs sulfonylurea.
A total of 47% of all initiators in our study 
underwent ≥1 screening mammogram over the 
two-year time window, far less than that reported by 
the U.S. Centers for Disease Control and Prevention
Metformin has a beneficial effect on weight loss which
may lead to more frequent or better detection.
Sulfonylurea users may receive more medical attention
due to severe adverse effect such as hypoglycemia and
this may detract from on cancer screenings.
Differential detection of breast cancer due to differ-
ential screening mammography before and after drug
initiation has distinct influences on effect estimates,
thus our results need to be interpreted separately.
Differential screening mammography before initiation
which we observed in the new user cohort suggests
that metformin initiators may be at slightly lower risk
of breast cancer than sulfonylurea initiators at the time
of initiation because more women with asymptomatic
breast cancer were excluded from the metformin
group, despite the fact that the difference in the proba-
bility of screen-detected breast cancer was small.
On the other hand, differential screening mammog-
raphy after initiation may increase breast cancer
incidence in metformin initiators immediately
following treatment initiation and may decrease breast
cancer incidence thereafter because of the detection of
Table 2. Frequency of screening mammograms and screen-detected breast cancer over 2 years in the new user cohort, by treatment group and by time interval
before and after initiation
Clinical Event Mammograms over 24 months
Screening mammograms before and after initiation
12 months before initiation 12 months after initiation
Cohort MET SUL MET SUL MET SUL#
Total Patients, n 41,436 13,367 41,436 13,367 41,436 13,367
Screening Mammography¶
N of screening mammograms 29,597 6,567 14,347 3,226 15,250 3,341
N of patients receiving ≥ 1 screening
mammogram, n (%)
20,847 (50.3) 4,767 (35.7) 14,328 (34.6) 3,223 (24.1) 15,223 (36.7) 3,337 (25.0)
Crude RD,% (95% CI)* 14.6 (13.7, 15.6) 10.5 (9.6, 11.3) 11.8 (10.9, 12.6)
Weighted RD,% (95% CI)*,† 8.4 (7.4, 9.5) 6.4 (5.4, 7.4) 6.8 (5.8, 7.8)
Breast Cancer detected at Screening‡, ¶
Screen-detected BC case, n (%) 197 (0.48) 37 (0.28) 73 (0.18) 20 (0.15) 124 (0.30) 17 (0.13)
Crude RD,% (95% CI)* 0.20 (0.09, 0.31) 0.03 (-0.05, 0.10) 0.17 (0.09, 0.25)
Weighted RD,% (95% CI)*,† 0.11 (-0.03, 0.25) 0.00 (-0.09, 0.09) 0.11 (0.00, 0.21)
Screening detection rate for breast
cancer per 1,000 tests§
6.7 (5.7, 7.6) 5.6 (3.8, 7.4) 5.1 (3.9, 6.3) 6.2 (3.5, 8.9) 8.1 (6.7, 9.6) 5.1 (2.7, 7.5)
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylurea; RD: risk difference.
*RD was estimated comparing metformin initiators to sulfonylurea initiators.
†Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin initiators and the odds of the estimated propensity
score for sulfonylurea initiators. Propensity score model included age (in years), age-squared, race category (white, black, and others), congestive heart failure
(Yes/No), ischemic heart disease (Yes/No), hypertension (Yes/No), cancer (Yes/No), calendar year of initiation, and number of physician visit in 12 months
prior to initiation (classified as ≤ 6, 7 to 12, and ≥13).
§Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided by total number of screening mammograms.
The overall detection rate for screen-detected breast cancer was 6.5 per 1,000 screening examinations in our study, similar to the Breast Cancer Surveillance
Consortium 2009 data which ranges from 6.1 to 8.5 as age increases from 65 to 85+.27
‡We conducted a sensitivity analysis in which a surgery was not required for a breast cancer diagnosis to identify incident breast cancer detected at screening
mammography (Supplemental Table S4). The risk of screen-detected breast cancer between metformin and sulfonylurea initiators over 24 months was 0.22
percentage points (95% CI: 0.04, 0.40) after propensity score adjustment.
¶We compared the performance of the algorithms between women aged <75 years and women aged 75 or older (Supplemental Table S6) and found no dif-
ference. The percentage of screening mammograms identified from all mammograms was 84% in women aged <75 and 82% in women aged 75 or older. The
screening detection rate for breast cancer per 1,000 tests was 6.6 and 6.3 in women aged <75 or 75+ years, respectively.
#We examined the impact of subsequent addition of metformin on use of screening mammograms by stratifying sulfonylurea initiators based on subsequent
addition of metformin in 12 months after initiation (Supplemental Table S7). 29% and 24% of sulfonylurea initiators adding and not adding metformin later
received screening mammograms in 12 months, respectively, which were still lower than metformin initiators (37%).
because mammography is recommended for women 
aged 50-74. Sulfonylurea initiators were older than 
metformin initiators, thus resulting in a lower propor-
tion of women being screened. Nevertheless, differen-
tial screening between metformin and sulfonylurea 
initiators remains apparent after we controlled imbal-
ance in age and patient characteristics by propensity 
score weighting. We hypothesize that it could also be 
related to prescriber’s behavior. Previous studies have 
shown that physician recommendation is a strong 
motivation for undergoing screening mammogra-
phy.24,25 Given that metformin is recommended as 
the preferred initial treatment for diabetes, metformin 
prescribers who comply with guideline recommenda-
tions may be more likely to perform regular examina-
tions or to recommend cancer screening tests for older 
patients. Thus, women initiating metformin may be 
more likely to receive screening mammography and, 
consequently, to be diagnosed with breast cancer 
around the time of initiation. Besides, there is a possi-
bility that use of metformin or sulfonylurea itself 
might alter the probability of being screened.
time-window for the cancer to develop and be
detected. On the other hand, differential screening
after initiation could lead to a relative lower risk of
breast cancer for metformin initiators given more cases
of screen-detected breast cancer are excluded from
metformin initiators than sulfonylurea initiators during
the lag period. Together, our results on differential
screening mammography are unlikely to explain why
we would observe a null association between metfor-
min in comparison with sulfonylurea and breast cancer
as observed in some studies assuming a real protective
effect of metformin.5,8,9 Our results might, however,
partially explain a reduced risk of breast cancer associ-
ated with metformin as observed in one cohort study
with sulfonylurea as a comparison group3 and in
several studies with different comparison groups1,2,7
assuming no effect of metformin on breast cancer
incidence.
Table 3. Frequency of screening mammograms, screen-detected breast cancer, and any breast cancer over 12 months after initiation in the cancer-free cohort,
by treatment group and by receipt of screening mammography within 12 months prior to initiation.
Clinical Event
Mammograms in 12 months after
initiation
Receipt of screening mammography within 12 months prior to initiation
Yes No
Cohort MET SUL** MET SUL MET SUL
Total Patients, n 35,826 11,359 13,007 2,808 22,819 8,551
Screening Mammography&
N of screening mammograms 13,894 2,961 8,040 1,587 5,854 1,374
N of patients receiving ≥ 1
screening mammogram, n (%)
13,868 (38.7) 2,957 (26.0) 8,028 (61.7) 1,585 (56.4) 5,840 (25.6) 1,372 (16.0)
Crude RD,% (95% CI)* 12.7 (11.7, 13.6) 5.3 (3.3, 7.3) 9.5 (8.6, 10.5)
Weighted RD,% (95% CI)*, † 5.4 (4.2, 6.5) 4.2 (2.0, 6.4) 6.0 (4.8, 7.1)
Breast Cancer detected at Screening#, &
Screen-detected BC case, n (%) 114 (0.32) 15 (0.13) 42 (0.32) <11 (<0.39) ¶ 72 (0.32) <11 (<0.13) ¶
Crude RD,% (95% CI)* 0.19 (0.10, 0.27) N/S¶ N/S¶
Weighted RD,% (95% CI)*, † 0.11 (-0.02, 0.23) -0.06 (-0.35, 0.23) 0.20 (0.08, 0.31)
Screening detection rate for breast
cancer per 1,000 tests§
8.2 (6.7, 9.7) 5.1 (2.5, 7.6) 5.2 (3.6, 6.8) N/S¶ 12.3 (9.5, 15.1) N/S¶
Any Incident Breast Cancer
BC cases (%) 186 (0.52) 41 (0.36) 58 (0.45) 14 (0.50) 128 (0.56) 27 (0.32)
Crude RD,% (95% CI)* 0.16 (0.03, 0.29) -0.05 (-0.34, 0.23) 0.25 (0.09, 0.40)
Weighted RD,% (95% CI)* 0.09 (-0.07, 0.26) -0.15 (-0.50, 0.20) 0.23 (0.06, 0.40)
% of BC detected by screening‡ 61.3 (54.3, 68.3) 36.6 (21.8, 51.3) 72.4 (60.9, 83.9) N/S¶ 56.3 (47.7, 64.8) N/S¶
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylurea; RD: risk difference; N/S: not specified.
*RD was estimated comparing metformin initiators to sulfonylurea initiators.
†Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin initiators and the odds of the estimated propensity
score for sulfonylurea initiators. Propensity score model included age (in years), age-squared, race category (white, black, and others), congestive heart failure
(Yes/No), ischemic heart disease (Yes/No), hypertension (Yes/No), cancer (Yes/No), calendar year of initiation, and number of physician visit in 12 months
prior to initiation (classified as ≤ 6, 7 to 12, and ≥13)
§Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided by total number of screening mammograms.
‡Percent of breast cancer detected by screening was calculated by cases of screen-detected breast cancer divided by total cases of breast cancers
¶Our DUA does not allow us to present cell sizes <11, so the number for these cells were not presented on this table.
#We conducted a sensitivity analysis in which a surgery was not required for a breast cancer diagnosis to identify incident breast cancer detected at screening
mammography (Supplemental Table S5). The risk of screen-detected breast cancer between metformin and sulfonylurea initiators was 0.18 percentage points
(95% CI: 0.04, 0.32) after propensity score adjustment.
&We compared the performance of the algorithms between women aged <75 years and women aged 75 or older (Supplemental Table S6) and found no
difference. The percentage of screening mammograms identified from all mammograms was 91% in women aged <75 and 97% in women aged 75 or older.
The screening detection rate for breast cancer per 1,000 tests was 7.6 and 7.8 in women aged <75 or 75+ years, respectively.
**We examined the impact of subsequent addition of metformin on use of screening mammograms by stratifying sulfonylurea initiators based on subsequent
addition of metformin in 12 months after initiation (Supplemental Table S8). 30% and 25% of sulfonylurea initiators adding and not adding metformin later
received screening mammograms in 12 months, respectively, which were still lower than metformin initiators (39%).
preclinical breast cancer that may eventually become 
clinical and be diagnosed without screening. One 
cohort study examined metformin users in the UK 
Clinical Practice Research Datalink (CPRD) and 
found a pattern of higher breast cancer risk in the first 
6 months since initiation compared with later4, 
supporting our hypothesis. This may also explain the 
unexpected increased incidence of breast cancer in 
metformin users which was observed in one cohort 
study of US Medicare claims10, and, in addition to 
time-related bias12, might also partially explain the 
benefits of metformin on breast cancer incidence 
which was only observed after long-term treatment in 
one CPRD case-control study.1
Cohort studies of cancer incidence usually consider 
a lag period of 6 or 12 months and follow-up begins 
after the lag period. The lag period is important 
because it explicitly incorporates into the analysis a
be aware of the potential for more screening mammo-
grams pre- and post-initiation when interpreting the
findings of studies assessing the effects of metformin
on breast cancer incidence.
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In the cancer-free cohort, increased risks of screen-
detected breast cancer and all breast cancer in metfor-
min initiators were confined to women not screened 
previously. Differential detection has little impact on 
the association between metformin and breast cancer 
incidence among women previously screened. The 
findings suggest that restricting the study population 
to women with prior screening may be effective to 
reduce detection bias due to differential use of screen-
ing mammography. In addition, estimating the propor-
tion of study population receiving screening 
mammograms before and after initiation can be useful 
to quantify the impact of differential detection.
This study has some limitations. First, our study is 
limited by the small number of screen-detected breast 
cancer cases, thus the effect estimates (i.e., RD) were 
imprecise. We acknowledge that this impacted our 
ability to detect a small difference in the risk of 
screen-detected breast cancer during the study period. 
Secondly, we may have underestimated true cases of 
breast cancer detected at screening. To ascertain breast 
cancer cases, we required a breast surgery following a 
breast cancer diagnosis, according to the Fenton algo-
rithm.14 Although surgery is the primary and most 
effective treatment for breast cancer, it is possible that 
older women with comorbid conditions may not 
undergo surgery.26 Thirdly, there might be residual 
confounding by age. After propensity score adjust-
ment, metformin and sulfonylurea initiators were 
marginally comparable in age. Imbalance in age may 
still remain among extremely old patients with comor-
bidities, but is expected to be small. In addition, given 
the limited sample size, we did not use information on 
prescriber’s characteristics to evaluate our hypothesis 
that differential screening may be related to 
prescriber’s behavior. Although the algorithms used 
in this study been validated within Medicare claims, 
we acknowledge the difficulty to distinguish true 
screening from diagnostic mammography because 
women with symptoms may be more likely to undergo 
screening. Lastly, Medicare part B plans provide free 
annual screening mammography for women aged 65
+, reducing health inequalities for receiving mammog-
raphy. Thus, our results can be generalized to US older 
women, but may not be generalized to younger women 
or women residing in other countries where socioeco-
nomic status likely affects the probability of receiving 
screening mammography.
Our study provides empirical evidence for biased 
detection for breast cancer due to more screening 
mammograms being performed in older women 
initiating metformin compared with sulfonylurea 
around the time of drug initiation. Researchers should
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KEY POINTS
• In the US, older women initiating metformin are
more likely than those initiating sulfonylurea to
be screened for breast cancer in the year before
and after initiation.
• More screening mammography pre-initiation
would tend to reduce breast cancer incidence in
metformin initiators; in contrast, more screening
mammography post-initiation would tend to
increase breast cancer incidence in metformin
initiators.
• Researchers should be aware of the potential for
more screening mammograms in women
initiating metformin vs sulfonylurea pre- and
post-initiation when interpreting the findings of
metformin on breast cancer incidence.
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